Franco L, Manara P, Erbetti I, Velo G P
Istituto di Farmacologia, Università di Verona, Italy.
Pharmacol Res. 1993 Feb-Mar;27(2):141-50. doi: 10.1006/phrs.1993.1014.
We have investigated the ability of carbenoxolone and ISF 3041, a new carbenoxolone derivative, to protect the rat gastric and intestinal mucosa against lesions induced by acetylsalicyclic acid (ASA) and indomethacin. Moreover, we determined the capacity of the rat gastric mucosa to release PGE2 both in vitro and ex vivo, in the presence or absence of carbenoxolone or its analogs. These compounds are effective against lesions induced by ASA and intestinal damage induced by indomethacin. The amount of PGE2 obtained from incubated rat gastric mucosal pieces by in vitro and ex vivo indicate that carbenoxolone and ISF 3401 cause a concentration related increase of PGE2 with exception of the highest concentration. Increased prostaglandin content of gastric mucosa can partly explain the gastric and intestinal protection of these compounds and additional mechanisms could be involved in this action.
我们研究了生胃酮和一种新的生胃酮衍生物ISF 3041保护大鼠胃和肠黏膜免受乙酰水杨酸（ASA）和吲哚美辛所致损伤的能力。此外，我们测定了在有或无生胃酮或其类似物存在的情况下，大鼠胃黏膜在体外和体内释放前列腺素E2（PGE2）的能力。这些化合物对ASA所致损伤和吲哚美辛所致肠损伤有效。通过体外和体内实验从孵育的大鼠胃黏膜片中获得的PGE2量表明，除最高浓度外，生胃酮和ISF 3401可引起PGE2浓度相关的增加。胃黏膜中前列腺素含量的增加可部分解释这些化合物对胃和肠的保护作用，且此作用可能涉及其他机制。
